[go: up one dir, main page]

NO995231D0 - Terapeutisk behandling av hudlidelser - Google Patents

Terapeutisk behandling av hudlidelser

Info

Publication number
NO995231D0
NO995231D0 NO995231A NO995231A NO995231D0 NO 995231 D0 NO995231 D0 NO 995231D0 NO 995231 A NO995231 A NO 995231A NO 995231 A NO995231 A NO 995231A NO 995231 D0 NO995231 D0 NO 995231D0
Authority
NO
Norway
Prior art keywords
therapeutic treatment
skin disorders
disorders
skin
therapeutic
Prior art date
Application number
NO995231A
Other languages
English (en)
Other versions
NO995231L (no
Inventor
Michael R Jirousek
Lawrence E Stramm
Louis Vignati
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO995231D0 publication Critical patent/NO995231D0/no
Publication of NO995231L publication Critical patent/NO995231L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
NO995231A 1997-04-30 1999-10-26 Terapeutisk behandling av hudlidelser NO995231L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4443197P 1997-04-30 1997-04-30
PCT/US1998/007808 WO1998048795A1 (en) 1997-04-30 1998-04-21 Therapeutic treatment for skin disorders

Publications (2)

Publication Number Publication Date
NO995231D0 true NO995231D0 (no) 1999-10-26
NO995231L NO995231L (no) 1999-12-27

Family

ID=21932346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995231A NO995231L (no) 1997-04-30 1999-10-26 Terapeutisk behandling av hudlidelser

Country Status (16)

Country Link
US (1) US6093740A (no)
EP (1) EP0903145A3 (no)
JP (1) JP2002501501A (no)
KR (1) KR20010020381A (no)
CN (1) CN1259866A (no)
AU (1) AU7131898A (no)
BR (1) BR9809343A (no)
CA (1) CA2289257A1 (no)
EA (1) EA199900987A1 (no)
HU (1) HUP0002836A2 (no)
ID (1) ID23528A (no)
IL (1) IL132520A0 (no)
NO (1) NO995231L (no)
PL (1) PL336760A1 (no)
TR (1) TR199902682T2 (no)
WO (1) WO1998048795A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140173B2 (en) * 1998-12-22 2013-04-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
ATE392215T1 (de) * 1999-12-22 2008-05-15 Scripps Research Inst Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
JP3429297B1 (ja) 2002-02-20 2003-07-22 株式会社ノエビア 皮膚外用剤
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
JP2009523807A (ja) * 2006-01-18 2009-06-25 ザ ジェネラル ホスピタル コーポレイション リンパ機能を高める方法
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
CN101380317B (zh) * 2007-09-07 2010-12-08 英属开曼群岛商安盛开发药物股份有限公司 减缓搔痒症的药学组合物
AU2012271781C1 (en) * 2011-06-13 2017-09-21 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
WO2018118874A1 (en) * 2016-12-19 2018-06-28 Chromaderm, Inc. Methods of treating hyperpigmentation disorders
EP4525862A1 (en) 2022-05-20 2025-03-26 Dermbiont, Inc. Compositions and formulations for use of a pk inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DK0657411T3 (da) * 1993-12-07 1999-11-15 Lilly Co Eli Forbedret syntese af bisindolylmaleimider
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
UA44690C2 (uk) * 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
PE22798A1 (es) * 1995-11-20 1998-05-11 Lilly Co Eli Inhibidor de proteina quinasa c
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
AU736333B2 (en) * 1996-05-01 2001-07-26 Eli Lilly And Company Therapeutic treatment for VEGF related diseases

Also Published As

Publication number Publication date
NO995231L (no) 1999-12-27
HUP0002836A2 (hu) 2001-02-28
BR9809343A (pt) 2000-07-04
KR20010020381A (ko) 2001-03-15
WO1998048795A1 (en) 1998-11-05
EP0903145A2 (en) 1999-03-24
TR199902682T2 (xx) 2000-05-22
CN1259866A (zh) 2000-07-12
ID23528A (id) 2000-04-27
AU7131898A (en) 1998-11-24
EP0903145A3 (en) 2001-02-07
CA2289257A1 (en) 1998-11-05
PL336760A1 (en) 2000-07-17
EA199900987A1 (ru) 2000-08-28
US6093740A (en) 2000-07-25
JP2002501501A (ja) 2002-01-15
IL132520A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
NO982172D0 (no) Anvendelse av epinastin for behandling av smerter
NO972972L (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
NO994014D0 (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
IS5500A (is) Lyfjablöndur til öftrunar og meðferðar mýlildi ogtengdum sjúkdómum
FI963696L (fi) Geeli ihosairauksien hoitoon ja ihon desinfiointiin
ID25921A (id) Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
NO20005884L (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
ID18679A (id) Penggunaan terapi lanjutan
NO995231D0 (no) Terapeutisk behandling av hudlidelser
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
NO20020062L (no) Behandling av nevrotiske forstyrrelser
FI973023L (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
NO984432L (no) FremgangsmÕte for behandling av migrenesmerte
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
DE69822276T2 (de) Kräuter formulierung mit therapeutischer und kosmetischer verwendung zur behandlung von allgemeinen hauterkrankungen
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
ZA971607B (en) Methods of treatment of allergic diseases
NO20014812D0 (no) Fremgangsmåte for tilveiebringelse av kosmetisk/medisinsk terapi
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
IL131347A0 (en) Treatment of skin disorders
NO982562D0 (no) Sammensetning for behandling av smerte
ID24922A (id) Terapi kombinasi untuk pengobatan aids
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application